Abstract
Introduction
Factors driving asthma exacerbation risk (ExR) are not fully characterised. We modelled ExR in patients (pts) with moderate-severe asthma on regularly dosed inhaled corticosteroid (ICS) mono- or ICS-long-acting beta agonist combination therapy.
Aims
To characterise ExR in moderate-severe asthma.
Methods
Individual pt data (N=6722) from 9 randomised clinical trials were used to build a parametric hazard model of time to first exacerbation, considering symptom control (Asthma Control Questionnaire 5 [ACQ-5]), and baseline clinical/demographic characteristics e.g., body mass index (BMI), exacerbation history, and smoking status. Model validation used standard goodness-of-fit, graphical and statistical criteria.
Results
BMI, ACQ-5, previous exacerbation history, % predicted forced expiratory volume in 1 second (FEV1 % pred), sex, and smoking were risk factors for ≥1 exacerbation (pfrequency was lower in pts with well and partially controlled symptoms at baseline vs pts with poorly controlled symptoms (psmokers and females.
Conclusions
Our drug-disease modelling approach assessed the contribution of pt-specific factors and treatment choices to ExR in moderate-severe asthma. Symptom control, BMI, FEV1 % pred, exacerbation history, and sex contribute to ExR, irrespective of treatment.
Factors driving asthma exacerbation risk (ExR) are not fully characterised. We modelled ExR in patients (pts) with moderate-severe asthma on regularly dosed inhaled corticosteroid (ICS) mono- or ICS-long-acting beta agonist combination therapy.
Aims
To characterise ExR in moderate-severe asthma.
Methods
Individual pt data (N=6722) from 9 randomised clinical trials were used to build a parametric hazard model of time to first exacerbation, considering symptom control (Asthma Control Questionnaire 5 [ACQ-5]), and baseline clinical/demographic characteristics e.g., body mass index (BMI), exacerbation history, and smoking status. Model validation used standard goodness-of-fit, graphical and statistical criteria.
Results
BMI, ACQ-5, previous exacerbation history, % predicted forced expiratory volume in 1 second (FEV1 % pred), sex, and smoking were risk factors for ≥1 exacerbation (pfrequency was lower in pts with well and partially controlled symptoms at baseline vs pts with poorly controlled symptoms (psmokers and females.
Conclusions
Our drug-disease modelling approach assessed the contribution of pt-specific factors and treatment choices to ExR in moderate-severe asthma. Symptom control, BMI, FEV1 % pred, exacerbation history, and sex contribute to ExR, irrespective of treatment.
| Original language | English |
|---|---|
| Publication status | Accepted/In press - 19 Jul 2023 |
| Event | ERS 2023 International Congress - Duration: 7 Sept 2023 → 13 Sept 2023 https://www.ersnet.org/congress-and-events/congress/ |
Conference
| Conference | ERS 2023 International Congress |
|---|---|
| Period | 7/09/23 → 13/09/23 |
| Internet address |